Aurinia Pharmace Stock Price, News & Analysis

Aurinia Pharmaceuticals (NASDAQ: AUPH) has scheduled the release of its first quarter 2025 financial and operational results for May 12, 2025, before markets open. The company will host a conference call and webcast at 8:30 AM ET on the same day, where management will review the results and provide a business update. Investors can join via phone by dialing 877-407-9170 (domestic) or +1 201-493-6756 (international). A replay of the webcast will be available on Aurinia's website.

Aurinia Pharmaceuticals (NASDAQ: AUPH) has received a significant endorsement from Institutional Shareholder Services (ISS), a leading independent proxy advisor, for its upcoming 2025 Annual General Meeting scheduled for May 15, 2025.

ISS has recommended shareholders vote "FOR" all Board proposals, including:

• Approval of six director nominees
• Proposed auditor appointment
• Non-binding advisory vote on executive compensation
• Amendment to the Company's Equity Incentive Plan

Shareholders of record as of April 12, 2025, are eligible to vote. All votes must be submitted by 12:00 PM EST on May 13, 2025. Complete voting details and proposals are available in the proxy statement accessible through EDGAR and SEDAR+ platforms.

Concerned shareholders of Aurinia Pharmaceuticals (NASDAQ: AUPH) have announced their intention to withhold support for CEO Peter Greenleaf at the 2025 Annual Meeting. MKT Capital and Lucien Selce, significant stakeholders since 2019-2020, acknowledge positive changes under new Board Chair Kevin Tang, including:

• Board size reduction from 9 to 6 members
• Appointment of 4 new independent directors
• Discontinuation of non-core R&D programs saving $50M annually
• Launch of $150M share repurchase program
• Elimination of time-based RSUs for performance-based awards

Shareholders criticize Greenleaf's leadership, citing stock price depression at $8 (versus historical highs of $35), lack of transparency regarding patent infringement lawsuits against Hikma, Lotus, and Galenicum, and questionable compensation practices including 1.55M RSUs awarded despite underperformance. They demand Greenleaf's resignation and call for improved transparency, cost optimization, and receptiveness to M&A discussions.

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported strong financial results for Q4 and full-year 2024. Q4 total revenue reached $59.9M (up 33% YoY), with LUPKYNIS net product sales of $57.6M (up 36% YoY). The company achieved Q4 net income of $1.4M, compared to a loss of $26.9M in Q4 2023.

Full-year 2024 showed total revenue of $235.1M (up 34% YoY) and net product sales of $216.2M (up 36% YoY). The company reported annual net income of $5.8M, improving from a $78M loss in 2023. Cash position stood at $358.5M as of December 31, 2024.

For 2025 guidance, Aurinia expects total revenue of $250-260M and net product sales of $240-250M. The company also initiated a Phase 1 study of AUR200, a dual inhibitor for autoimmune diseases, with initial results expected in Q2 2025.

Aurinia Pharmaceuticals (NASDAQ: AUPH) has announced that it will release its 2024 fourth quarter and full year financial and operational results on February 27, 2025, before the market opens.

The company's management team will host a conference call and webcast at 8:30 am ET on the same day to review these results and provide a general business update. Interested parties can join the conference call by dialing 877-407-9170 (US) or +1 201-493-6756 (International).

A replay of the webcast will be available on Aurinia's website.

Aurinia Pharmaceuticals (NASDAQ: AUPH) welcomes the American College of Rheumatology's (ACR) 2024 guidelines for lupus nephritis (LN) treatment. The new guidelines recommend LUPKYNIS as first-line therapy in a triple immunosuppressive treatment regimen. Key highlights include steroid tapering to <5 mg/day by six months and achieving proteinuria target of <0.5g/g UPCR by 12 months. The AURORA 1 clinical study showed patients were 81% more likely to achieve complete renal response at 52 weeks with LUPKYNIS combination therapy versus standard treatment. Notably, >80% of patients reached steroid doses of <2.5mg/day by 16 weeks.

Aurinia Pharmaceuticals (NASDAQ: AUPH) presented four posters at ACR 2024, highlighting new data about lupus nephritis (LN) detection and LUPKYNIS® treatment. A key study using the American Rheumatology Network database revealed that 62% of 8,631 SLE patients showed signs suggesting LN, yet many weren't receiving proper kidney screenings. The analysis of Phase 3 AURORA 1 and 2 studies demonstrated significantly higher rates of sustained complete renal response in LUPKYNIS patients compared to placebo. The data emphasizes the need for enhanced LN screening and validates LUPKYNIS's long-term efficacy in treating active LN in adults.

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced its participation in the upcoming Jefferies Healthcare Conference in London, scheduled for November 19-21, 2024. The company's management team will engage in one-on-one meetings with investors and participate in a fireside chat and Q&A session on Wednesday, November 20, at 12:00 PM GMT/7:00 AM EST. The session will not be webcasted.